- Covance experts to present best practices for improving drug safety and reducing R&D time, cost -
PRINCETON, N.J., June 16 /PRNewswire-FirstCall/ -- Covance Inc. is pleased to announce the complete list of experts scheduled to present at the Drug Information Association's (DIA) 45th Annual Meeting from June 21-25, 2009 in San Diego, Calif.
The DIA Annual Meeting is the biopharmaceutical industry's largest, longest running, global, multidisciplinary event. This year's program offers learning opportunities for everyone and features the biggest names from industry, regulatory, and academia.
Building on the conference theme, "Better Medicines: Improving Safety with Every Step," Covance experts will present best practices for improving safety while reducing the time and cost of drug development, including:
June 22, 2009:
10:30 a.m. | Speaker: Krish Ghosh, PhD, vice president, resource management
1:30 p.m. | Session Chair: Robert Bader, PharmD, senior director, product safety, periapproval services
1:30 p.m. | Speaker: Russ Dixon, MD, medical director, early clinical development
3:30 p.m. | Speaker: Ross Rothmeier, senior director, EDC portfolio, clinical development services
June 23, 2009:
8:00 a.m. | Session Chair: Bruce Wagman, MBA, RN, RAC, vice president, regulatory affairs and quality assurance, clinical development services
9:30 a.m. | Poster Presentation: Ann Flandermeyer, BSN, PhD, MSN, RN, project management and clinical operations
9:30 a.m. | Poster Presentation: Jackie Miller-Giles, MT (ASCP), MS, global clinical pharmacology
2:00 p.m. | Speaker: Paul Baldrick, PhD, head of department, pharmaceutical regulatory affairs
2:00 p.m. | Session Chair: John Poland, PhD, senior director, regulatory policy, UK, clinical development services
4:00 p.m. | Session Chair: Edgar Adams, ScD, MS, executive director, epidemiology, periapproval services
4:00 p.m. | Session Chair: Eunice Franklin-Becker, MPH, senior project manager, registries and observational studies, periapproval services
4:00 p.m. | Session Chair: Mary Westrick, PhD, global vice president and general manager, clinical pharmacology
June 24, 2009:
8:30 a.m. | Session Chair: Tim G. Strauss, MA, executive director, business process improvement, clinical development services
10:30 a.m. | Session Chair: Mark Anderson, senior director, data management, clinical development services
1:30 p.m. | Speaker: Heather Almonte, MBA, RAC, senior manager, site activation, clinical development services
3:30 p.m. | Speaker: Christina Werremeyer, project manager, periapproval services
3:30 p.m. | Session Chair: Katie Margules, PharmD, MSc, senior director, clinical development services, Latin America
June 25, 2009:
8:30 a.m. | Session Chair: Ann Flandermeyer, BSN, PhD, MSN, RN, senior director, project management and clinical operations, clinical development services
8:30 a.m. | Speaker: Mike Hill, project manager, periapproval services
10:30 a.m. | Session Chair: Peter Thomas, PhD, senior program manager, strategic partnering & integrated drug development
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 25 countries, and more than 9,600 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.
About the Drug Information Association (DIA)
DIA serves more than 30,000 biopharmaceutical professionals from industry, academia, and regulatory agencies worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit www.diahome.org or call 215.442.6100.
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.
|SOURCE Covance Inc.|
Copyright©2009 PR Newswire.
All rights reserved